Zacks.com on MSN17h
FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra UseAlnylam Pharmaceuticals ALNY announced that the FDA has accepted its supplemental new drug application (sNDA) seeking the ...
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) – Investment analysts at Zacks Research increased their FY2024 ...
The FDA has accepted Alnylam’s supplemental New Drug Application for Amvuttra on the heels of BridgeBio’s Attruby nod, ...
Scotiabank analyst Greg Harrison maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) today and set a price target of $310.00.
BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted ...
Delving into the details, we found 5% of traders were bullish, while 84% showed bearish tendencies. Out of all the trades we spotted, 14 were puts, with a value of $931,387, and 5 were calls, valued ...
Alnylam Pharma (ALNY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Kostas Biliouris ...
The presumptive new CDC director, Dave Weldon, is a known vaccine safety skeptic. In contrast, the FDA choice — Johns Hopkins ...
PNC Financial Services Group Inc. boosted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 1.2% in ...
GlobalData on MSN8d
Alnylam reveals trial outcomes of nucresiran for ATTR amyloidosis treatmentThe study showed significant reductions in serum TTR levels in subjects after a single dose, with sustained effects over time ...
2025 will be a very eventful year for BridgeBio. In addition to the commercial launches of Attruby in the United States, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback